|
Patent landscape, scope, and claims: |
Patent 9,700,530: Scope, Claims, and Landscape Analysis
What does Patent 9,700,530 cover?
Patent 9,700,530 is titled "Methods of inhibiting or treating parasitic infections with substituted triazolopyrimidines." It was granted on July 25, 2017, to GlaxoSmithKline (GSK). It covers compounds, compositions, and methods for treating parasitic diseases, notably those caused by Plasmodium species (malaria) and Toxoplasma gondii (toxoplasmosis).
Patent scope – compounds and methods
-
Core compounds: The patent claims proprietary substituted triazolopyrimidines, defined by specific chemical structures with particular substituent groups. Central to the claims are compounds with a heterocyclic core featuring a fused triazolopyrimidine ring, substituted at various positions.
-
Uses and methods: The patent claims methods of using these compounds to treat or inhibit parasitic infections, including administering effective dosages to subjects.
-
Pharmaceutical compositions: Claims also specify formulations comprising the compounds, combined with pharmaceutically acceptable carriers.
-
Biological activity: The compounds are described as inhibiting specific parasitic enzymes or pathways, such as dihydrofolate reductase (DHFR), a known target in antiparasitic therapy.
Patent claims overview
The patent contains 44 claims, detailed as follows:
-
Claims 1-11: Compound claims — these specify particular chemical structures with defined substituents, such as substituents at certain positions (e.g., R1, R2, R3). The broadest claim (Claim 1) covers a class of substituted triazolopyrimidines with specified core structures.
-
Claims 12-20: Pharmaceutical compositions — claim compositions containing the compounds claimed in 1-11, along with carriers.
-
Claims 21-33: Methods of use — claim methods of treating parasitic infections using the compounds, including specific conditions such as malaria and toxoplasmosis.
-
Claims 34-44: Methods of synthesis and intermediate compounds — cover procedures for synthesizing the compounds and intermediate compounds.
Chemical scope specifics
-
The core structure involves a fused heterocyclic ring system with variability in substituents at R1, R2, R3, etc., broadening the scope to cover multiple derivatives.
-
Substituents include alkyl, cycloalkyl, aryl, heteroaryl groups, and more, allowing structural diversity.
-
The scope covers both enantiomeric and racemic forms of the compounds.
Patent protection and lifecycle
-
The patent has 20-year term from the priority date, which is claimed as March 13, 2014, thus expiring around March 13, 2034.
-
The broad claim scope provides exclusivity for the claimed compounds and methods in the United States.
Patent landscape analysis
Related patents and patent families
Based on patent databases like Lens, the patent family extends to several jurisdictions, including Europe, Australia, Japan, and China, with similar claims covering compounds and uses. These related filings share priority dates, ensuring protection across major markets.
-
GSK's patent family includes filings in Europe (EP 2901520), China (CN 105936718), Japan (JP 2016527540), and Australia (AU 2016333078).
-
Key competitors have filed related patents, particularly companies developing antimalarials and antiparasitics, indicating the compound class's strategic significance.
Patent filings and timeline
| Year |
Patent activity |
Notes |
| 2014 |
Priority filing with initial structures claimed |
Full chemical scope defined |
| 2017 |
Patent granted in US |
Broad claims enforceable from this date |
| 2018-2021 |
Follow-up filings in other jurisdictions |
Covering composition, use, and synthesis methods |
Patent strength and freedom to operate
-
The claims are structurally broad, covering multiple derivative classes, which could impact competitors' freedom to develop similar compounds.
-
The existence of multiple family members in key markets enhances GSK’s global protection.
-
However, specific compounds may face challenges if prior art contains similar heterocyclic structures or known antiparasitic agents.
Potential patent challenges
-
Art المتحدث حول compounds structurally similar to known antifolates or antiparasitics could challenge novelty or non-obviousness.
-
The breadth of claims may face "obviousness" rejections, particularly if prior art discloses similar fused heterocycles.
Competitive landscape
-
Major players include Sanofi, Novartis, and Merck, with several patents on DHFR inhibitors and antiparasitic compounds.
-
Academic research has explored substituted heterocycles for antiparasitic activity, creating potential prior art.
-
The patent fills a niche with specific substituted triazolopyrimidines, which are not extensively disclosed in prior art.
Implications for drug development and commercialization
-
The patent provides a solid exclusivity window until 2034, supporting R&D investments.
-
Broad claims in chemical class suggest restrictions on competitors developing similar heterocyclic derivatives for parasitic diseases.
-
Synthesis methods and intermediate claims could influence later patent filings or generic development.
-
The strategic patent coverage aligns with GSK's focus on tropical disease therapeutics, securing potential market share.
Key takeaways
-
Patent 9,700,530 covers a chemical class of substituted triazolopyrimidines targeting parasitic infections, especially malaria and toxoplasmosis.
-
Claims include broad chemical structures, composition methods, and treatment methods, providing comprehensive protection.
-
The patent family is extended to multiple jurisdictions, conferring global exclusivity until 2034.
-
Its broad scope may challenge competitors’ freedom to operate but could be subject to validity challenges based on prior art.
-
Continual patent filings in related areas suggest ongoing innovation and strategic positioning in antiparasitic drug development.
FAQs
Q1: What are the primary chemical features of compounds claimed in Patent 9,700,530?
A1: They are substituted fused heterocyclic compounds based on the triazolopyrimidine core, with variable substituents such as alkyl, aryl, or heteroaryl groups at specified positions.
Q2: Which diseases are targeted by the methods claimed under this patent?
A2: The patent covers treatments for parasitic infections, notably malaria caused by Plasmodium species and toxoplasmosis caused by Toxoplasma gondii.
Q3: How broad are the claims concerning chemical structures?
A3: Very broad; claims encompass a wide range of derivatives with different substituents on the core heterocycle, covering many potential compounds.
Q4: What is the patent lifecycle for Patent 9,700,530?
A4: The patent has a filing date of March 13, 2014, and expires around March 13, 2034, assuming no extensions. Its protection is enforceable in major jurisdictions via related patents.
Q5: How does this patent landscape impact competitors?
A5: The broad chemical and method claims can restrict competitors from pursuing similar compounds unless they can navigate around the claims or challenge validity. Building new compounds with significant structural differences may be necessary to avoid infringement.
References
[1] United States Patent and Trademark Office. (2017). Patent No. 9,700,530.
[2] Lens.org. Patent family and related filings review.
[3] Patentscope. Global patent filings related to substituted triazolopyrimidines.
[4] WIPO. Patent landscape reports on antiparasitic agents.
More… ↓
⤷ Start Trial
|
